CVM - CEL-SCI Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
13.96
-0.16 (-1.13%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close14.12
Open0.00
Bid0.00 x 900
Ask0.00 x 1800
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume680,142
Market Cap493.963M
Beta (5Y Monthly)3.01
PE Ratio (TTM)N/A
EPS (TTM)-0.71
Earnings DateFeb 11, 2020 - Feb 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateAug 27, 1996
1y Target Est18.00
  • Business Wire

    CEL-SCI to Participate in Upcoming Investor Conferences

    CEL-SCI to participate in upcoming investor conferences.

  • Business Wire

    CEL-SCI Announces Full Exercise of Over-allotment Option by Aegis Capital Corp.

    CEL-SCI announces full exercise of over-allotment option by Aegis Capital Corp.

  • Business Wire

    CEL-SCI Announces the Closing of Its $5.5 Million Underwritten Offering

    CEL-SCI announces the closing of its $5.5 million underwritten offering.

  • Company News For Dec 26, 2019
    Zacks

    Company News For Dec 26, 2019

    Companies In The News Are: SSNT, NLNK, CVM, AXE

  • Business Wire

    CEL-SCI Prices $5.5 Million Underwritten Public Offering of Common Stock

    CEL-SCI prices $5.5 million underwritten public offering of common stock

  • Business Wire

    CEL-SCI Announces Proposed Underwritten Public Offering of Common Stock

    CEL-SCI announces proposed underwritten public offering of common stock.

  • Hedge Funds Are Buying CEL-SCI Corporation (CVM)
    Insider Monkey

    Hedge Funds Are Buying CEL-SCI Corporation (CVM)

    Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]

  • Business Wire

    CEL-SCI Reports Fiscal 2019 Financial Results and Clinical & Corporate Developments

    CEL-SCI reports fiscal 2019 financial results and clinical and corporate developments.

  • ACCESSWIRE

    CEL-SCI Corporation to Present at The LD Micro Main Event (XII)

    VIENNA, VA / ACCESSWIRE / December 6, 2019 / CEL-SCI Corporation (NYSE American:CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the 12th annual LD Micro Main Event on Tuesday, December 10, 2019 at 2:00 PM PST or 5:00 PM EST. The Chief Executive Officer, Geert Kersten, will be presenting and meeting with investors. To access the live webcast and subsequent archived recordings for the presentation, please visit the Investor Relations section of the Company's website at https://cel-sci.com/new-investor-information/.

  • Business Wire

    CEL-SCI Corporation to Present at Dawson James Securities 5th Annual Small Cap Growth Conference

    CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that Geert Kersten, Chief Executive Officer, will be presenting at the Dawson James Securities Small Cap Growth Conference on Tuesday, October 29th at 10:55 a.m. ET. To access the live webcast and subsequent archived recordings for the presentation, please visit the Investor Relations section of the Company's website at https://cel-sci.com/new-investor-information/. Dawson James Securities, Inc., a member of FINRA/SIPC, is a full-service investment bank headquartered in Boca Raton, FL.

  • Business Wire

    CEL-SCI Corporation Issues Letter to Shareholders

    CEL-SCI Corporation (NYSE American: CVM) today issued a letter to its shareholders. We at CEL-SCI have been believers in the value of immunotherapy for treating cancer for decades before others recognized it’s potential. Now cancer immunotherapy has gone from “cannot work” to “this is the future”.

  • CVM: IDMC Nod & Target Price Raise
    Zacks Small Cap Research

    CVM: IDMC Nod & Target Price Raise

    By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT The Last Review? CEL-SCI Corporation (NYSE:CVM) today announced its second Independent Data Monitoring Committee (IDMC) review this year for the IT MATTERS Phase III Multikine study for head and neck cancer. We believe that the longer than expected duration of the trial combined with the IDMC recommendation to continue its

  • Business Wire

    CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head and Neck Cancer Study

    CEL-SCI Corporation (NYSE American: CVM) announced today that the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) has completed its recent review of the Phase 3 study data. The IDMC meets periodically to review the safety and efficacy of the ongoing Phase 3 study.

  • CVM: A Focus on LEAPS
    Zacks Small Cap Research

    CVM: A Focus on LEAPS

    By John Vandermosten, CFA NYSE:CVM While CEL-SCI (NYSE:CVM) has experienced outstanding performance over the last several quarters due to the anticipated readout of Multikine in the IT-MATTERS clinical trial, the company also has a platform technology in development that has impressive potential in treating a number of human diseases. This platform is known as the Ligand

  • These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now?
    Motley Fool

    These 3 Biotech Stocks Skyrocketed Last Week -- Are They Buys Now?

    These stocks were huge winners last week. But can their momentum continue?

  • Zacks Small Cap Research

    CVM: No Free Samples on Facility Tour

    In late May 2019, Zacks was treated to an onsite tour of CEL-SCI’s (CVM) 73,000 square foot manufacturing facility in Elkridge, Maryland. As we drove to the industrial park southwest of Baltimore, we came upon CEL-SCI’s facility, nestled among warehouses and light manufacturing enterprises. With multiple delivery bays and administrative offices up front, we entered to meet with Chief Scientific Officer Dr. Eyal Talor who introduced us to the staff and provided background on the facility in preparation for our walk through.

  • Benzinga

    The Companies Set To Join The Russell Index July 1

    OncoCyte Corporation (NYSE: OCX ) is set to join the Russell 2000, Russell 3000 and Russell Microcap Indexes July 1. The Russell 3000 Index is a capitalization-weighted stock market index maintained by ...

  • Business Wire

    CEL-SCI Corporation Set to Join Russell 3000® Index

    CEL-SCI Corporation (NYSE American: CVM) is set to join the broad-market Russell 3000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective after the US market opens on July 1, according to a preliminary list of additions posted June 7. Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 10, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes.

  • Business Wire

    CEL-SCI Corporation to Present at the 9th Annual LD Micro Invitational

    CEL-SCI Corporation (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4th at 10:40 a.m. PT. Geert Kersten, Chief Executive Officer of CEL-SCI, will be giving the presentation. Mr. Kersten’s presentation will be webcast and available in the Investor Relations section of the Company's website at https://cel-sci.com/new-investor-information/.

  • Zacks Small Cap Research

    CVM: Second Quarter 2019 Results

    By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT CEL-SCI Corporation (NYSE:CVM) reported fiscal second quarter 2019 results for the three month period ending March 31, 2019. A the end ...

  • Associated Press

    Cel-Sci: Fiscal 2Q Earnings Snapshot

    The Vienna, Virginia-based company said it had a loss of 22 cents per share. Losses, adjusted for non-recurring costs, were 19 cents per share. The cancer immunotherapy company posted revenue of $150,800 ...